Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$12.63 - $24.47 $124,266 - $240,760
-9,839 Reduced 30.64%
22,270 $526,000
Q3 2023

Nov 14, 2023

SELL
$10.86 - $17.62 $90,985 - $147,620
-8,378 Reduced 20.69%
32,109 $478,000
Q2 2023

Aug 14, 2023

BUY
$7.47 - $10.95 $302,437 - $443,332
40,487 New
40,487 $443,000
Q4 2021

Feb 14, 2022

SELL
$3.23 - $4.6 $34,166 - $48,658
-10,578 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$3.47 - $4.42 $36,705 - $46,754
10,578 New
10,578 $39,000
Q1 2021

May 17, 2021

SELL
$4.23 - $6.55 $381,634 - $590,947
-90,221 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$5.73 - $9.03 $516,966 - $814,695
90,221 New
90,221 $518,000
Q1 2020

May 15, 2020

SELL
$1.25 - $2.02 $22,918 - $37,036
-18,335 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$1.33 - $5.93 $24,385 - $108,726
18,335 New
18,335 $36,000
Q1 2019

May 14, 2019

SELL
$8.16 - $13.42 $179,462 - $295,146
-21,993 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$6.54 - $11.74 $121,663 - $218,399
-18,603 Reduced 45.82%
21,993 $173,000
Q3 2018

Nov 15, 2018

BUY
$10.88 - $14.52 $76 - $101
7 Added 0.02%
40,596 $450,000
Q2 2018

Aug 14, 2018

BUY
$10.66 - $14.38 $432,678 - $583,669
40,589 New
40,589 $545,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.